Menu Search
Equities

Moleculin Biotech Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0K2H:LSE

Moleculin Biotech Inc

Actions
  • Price (USD)4.35
  • Today's Change0.000 / 0.00%
  • Shares traded1.37k
  • 1 Year change-68.27%
  • Beta1.6651
Data delayed at least 20 minutes, as of Feb 10 2026 16:40 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

  • Revenue in USD (TTM)0.00
  • Net income in USD-41.36m
  • Incorporated2015
  • Employees17.00
  • Location
    Moleculin Biotech Inc5300 Memorial Dr Ste 950HOUSTON 77007-8274United StatesUSA
  • Phone+1 (713) 300-5160
  • Fax+1 (302) 636-5454
  • Websitehttps://moleculin.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.